Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07616154 · ClinicalTrials.gov registry record · Phase 2
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Not yet
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT07616154 is a Phase 2 study that has not yet begun recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 45 participants.
The verdict
NCT07616154, a Phase 2 study, has not yet begun recruiting, sponsored by St. Jude Children's Research Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greater than 90% after haploidentical donor HCT in children and young adults with SCD. Primary Objective: \- To assess the GVHD-free and rejection free survival (GRFS) after haploidentical donor HCT in children and young adults with SCD. Secondary Objectives: * Assess the overall survival (OS) and disease-free survival (DFS) after haploidentical donor HCT for SCD. * Estimate incidence and severity of acute and chronic GVHD after haploidentical donor HCT for SCD. * Assess the neutrophil and platelet engraftment kinetics after haploidentical donor HCT for SCD.
Interventions
- DRUG Alemtuzumab
- DRUG Hydroxyurea
- DRUG Abatacept
- DRUG Thiotepa
- DRUG Cyclophosphamide 50mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-09 |
| Est. Completion | 2035-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07616154
The ClinicalTrials.gov registry entry for NCT07616154 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Alemtuzumab is the first listed.
NCT07616154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07616154 about?
NCT07616154 is a clinical study titled "Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease". The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greate...
What is the current status of trial NCT07616154?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2026-09. Estimated completion is 2035-09.
What interventions are being tested in trial NCT07616154?
The interventions under investigation include: Alemtuzumab (DRUG), Hydroxyurea (DRUG), Abatacept (DRUG), Thiotepa (DRUG), Cyclophosphamide 50mg (DRUG).
Who is sponsoring clinical trial NCT07616154?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.